ImmuCell director granted 11,933 stock options

ImmuCell Corp director Paul R. Wainman received a new stock option grant as part of his compensation.

Rhea-AI Filing Summary

ImmuCell Corp director Paul R. Wainman received a new stock option grant as part of his compensation. He was awarded options to buy 11,933 shares of ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.

The options vest over three years: 3,977 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares on April 15, 2029. After this grant, Wainman holds 11,933 stock options directly, indicating a compensation-related equity award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 11,933 shares

Grant/Award 1 txn

Insider Wainman Paul R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non Qualified Stock Options (Right to buy)	11,933	$0.00	$0.00

Holdings After Transaction: Non Qualified Stock Options (Right to buy) — 11,933 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029.

Key Figures

Options granted: 11,933 options Exercise price: $7.60 per share Expiration date: April 15, 2036 +4 more

7 metrics

Options granted 11,933 options Non-qualified stock options granted to director on April 15, 2026

Exercise price $7.60 per share Exercise price for the 11,933 non-qualified stock options

Expiration date April 15, 2036 Expiry of the granted non-qualified stock options

Vesting 2027 3,977 options First tranche becoming exercisable on April 15, 2027

Vesting 2028 3,977 options Second tranche becoming exercisable on April 15, 2028

Vesting 2029 3,979 options Final tranche becoming exercisable on April 15, 2029

Options held after grant 11,933 options Total non-qualified stock options held directly after transaction

Key Terms

Non Qualified Stock Options, exercise price, vesting, Common Stock

4 terms

Non Qualified Stock Options financial

"security_title: "Non Qualified Stock Options (Right to buy)""

exercise price financial

"conversion_or_exercise_price: "7.6000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock option vests as follows: 3,977 shares becoming exercisable..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ImmuCell (ICCC) director Paul R. Wainman report in this Form 4?

Paul R. Wainman reported receiving a grant of non-qualified stock options for 11,933 ImmuCell common shares. These options are compensation-related, not an open-market trade, and give him the right to buy shares at a fixed exercise price in the future.

How many ImmuCell (ICCC) options were granted to Paul R. Wainman and at what price?

He was granted 11,933 non-qualified stock options with an exercise price of $7.60 per share. This price is the cost per share if he later chooses to exercise the options and acquire ImmuCell common stock.

When do Paul R. Wainman’s ImmuCell (ICCC) stock options vest?

The options vest in three installments: 3,977 shares become exercisable on April 15, 2027, another 3,977 on April 15, 2028, and the remaining 3,979 on April 15, 2029. Vesting means he can begin exercising those portions on those dates.

When do the newly granted ImmuCell (ICCC) options to Paul R. Wainman expire?

The non-qualified stock options expire on April 15, 2036. After that date, any unexercised options will lapse, meaning Wainman would no longer be able to buy ImmuCell shares at the $7.60 exercise price through this grant.

Is Paul R. Wainman’s ImmuCell (ICCC) Form 4 a stock purchase or sale?

This Form 4 reflects a grant or award of stock options, categorized as an acquisition of a derivative security. It is not an open-market stock purchase or sale but part of his equity-based compensation as a director of ImmuCell.

How many ImmuCell (ICCC) options does Paul R. Wainman hold after this transaction?

Following this grant, Wainman directly holds 11,933 non-qualified stock options. These options represent potential future ownership of the same number of ImmuCell common shares if he chooses to exercise them at the stated $7.60 exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 03:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wainman Paul R

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non Qualified Stock Options (Right to buy)	$7.6	04/15/2026		A		11,933		(1)	04/15/2036	Common Stock	11,933	$0	11,933	D

Explanation of Responses:

1. The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029.

Remarks:

The options were granted by the issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)